ATE272636T1 - Naphthyridine die den rezeptor il-4 und den faktor g-csf beeinflussen - Google Patents

Naphthyridine die den rezeptor il-4 und den faktor g-csf beeinflussen

Info

Publication number
ATE272636T1
ATE272636T1 AT97932142T AT97932142T ATE272636T1 AT E272636 T1 ATE272636 T1 AT E272636T1 AT 97932142 T AT97932142 T AT 97932142T AT 97932142 T AT97932142 T AT 97932142T AT E272636 T1 ATE272636 T1 AT E272636T1
Authority
AT
Austria
Prior art keywords
naphthyridines
receptor
affect
csf factor
compounds
Prior art date
Application number
AT97932142T
Other languages
English (en)
Inventor
Daniel M Solomon
Michael J Grace
Jay S Fine
Loretta A Bober
Margaret H Sherlock
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Application granted granted Critical
Publication of ATE272636T1 publication Critical patent/ATE272636T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT97932142T 1996-06-20 1997-06-18 Naphthyridine die den rezeptor il-4 und den faktor g-csf beeinflussen ATE272636T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US66918596A 1996-06-20 1996-06-20
PCT/US1997/009202 WO1997048368A2 (en) 1996-06-20 1997-06-18 Naphthyridines which affect il-4 and g-csf

Publications (1)

Publication Number Publication Date
ATE272636T1 true ATE272636T1 (de) 2004-08-15

Family

ID=24685412

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97932142T ATE272636T1 (de) 1996-06-20 1997-06-18 Naphthyridine die den rezeptor il-4 und den faktor g-csf beeinflussen

Country Status (9)

Country Link
EP (1) EP0912571B1 (de)
JP (2) JP4181220B2 (de)
CN (1) CN1228090A (de)
AT (1) ATE272636T1 (de)
AU (1) AU3567397A (de)
CA (1) CA2258752C (de)
DE (1) DE69730137T2 (de)
ES (1) ES2225980T3 (de)
WO (1) WO1997048368A2 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1228090A (zh) * 1996-06-20 1999-09-08 先灵公司 影响il－4和g－csf的二氮萘
AU775701B2 (en) 1999-02-08 2004-08-12 G.D. Searle & Co. Sulfamato hydroxamic acid metalloprotease inhibitor
US6800646B1 (en) 1999-02-08 2004-10-05 Pharmacia Corporation Sulfamato hydroxamic acid metalloprotease inhibitor
EP2292593A3 (de) * 2000-09-29 2011-05-25 TopoTarget UK Limited Carbamidsäureverbindungen mit einer Sulfonamid enthaltenden Verkettung als HDAC Inhibitoren
CN1551766A (zh) * 2001-09-05 2004-12-01 ������������ʽ���� 淋巴细胞活化抑制剂和自身免疫性疾病治疗剂
CA2483314A1 (en) 2002-04-25 2003-11-06 Pharmacia Corporation Piperidinyl-and piperazinyl-sulfonylmethyl hydroxamic acids and their use as protease inhibitors
EP1791842A1 (de) * 2004-09-14 2007-06-06 Novartis AG Verfahren zur herstellung von 6,8-substituierten 1,7-naphthpyridinderivaten durch umsetzung des 8-halogen-1,7-naphthpyridinderivats mit organischen boronsäurederivaten, und zwischenprodukte dieses verfahrens
DE102008019838A1 (de) * 2008-04-19 2009-12-10 Boehringer Ingelheim International Gmbh Neue Arylsulfonylglycin-Derivate, deren Herstellung und deren Verwendung als Arzneimittel

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2550575A1 (de) * 1975-11-11 1977-05-12 Scherico Ltd Naphthyridine, verfahren zu ihrer herstellung und sie enthaltende arzneimittel
GB1545767A (en) * 1976-06-30 1979-05-16 Aspro Nicholas Ltd Isoquinoline derivatives
US4942163A (en) * 1989-03-07 1990-07-17 E. I. Du Pont De Nemours And Company 1(2H)-isoquinolinones and 1-isoquinolineamines as cancer chemotherapeutic agents
CN1228090A (zh) * 1996-06-20 1999-09-08 先灵公司 影响il－4和g－csf的二氮萘

Also Published As

Publication number Publication date
WO1997048368A2 (en) 1997-12-24
EP0912571A2 (de) 1999-05-06
CA2258752C (en) 2006-08-15
JP2008255119A (ja) 2008-10-23
JP2002501472A (ja) 2002-01-15
CA2258752A1 (en) 1997-12-24
AU3567397A (en) 1998-01-07
EP0912571B1 (de) 2004-08-04
WO1997048368A3 (en) 1998-02-05
DE69730137T2 (de) 2005-07-14
CN1228090A (zh) 1999-09-08
JP4181220B2 (ja) 2008-11-12
ES2225980T3 (es) 2005-03-16
DE69730137D1 (de) 2004-09-09

Similar Documents

Publication Publication Date Title
IL112778A0 (en) Substituted heterocycles, their preparation and pharmaceutical compositions containing them
IL133988A0 (en) Indole derivatives as mcp-1 receptor antagonists
DE69816091D1 (de) Indol-derivate und ihre anwendung als mcp-1 antagonisten
MY112102A (en) Therapeutic heterocycles.
KR100246065B1 (en) Substituted 3-aminoquinuclidines
EP0709375A3 (de) Therapeutisch wirksame Heterocyclen
IL98860A0 (en) Quinuclidine derivatives
BG103399A (en) New heterocycle-substituted benzamides and their application for the treatment of diseases
ZA969621B (en) Therapeutic compounds
IL200484A0 (en) Use of wisp polypeptides wisp for the preparation of medicaments
ATE201671T1 (de) Chinolon und acridinon derivate zur behandlung der harninkontinenz
GR3033528T3 (en) Novel piperidine derivatives with paf antagonist activity
GB9502644D0 (en) Heterocyclic derivatives
NZ330944A (en) Peptide derivatives
DE69730137D1 (de) Naphthyridine die den rezeptor il-4 und den faktor g-csf beeinflussen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties